➤ 36- and 48-month efficacy demonstrated with canaloplasty ➤ Phase 1/2 trial for gene therapy for X-linked retinitis pigmentosa ➤ Topline results from Phase 2a trial for possible DME therapy ➤ Preclinical data shows potential for gene therapy to address Leber congenital amaurosis ➤ ASCRS news and events

➤ FDA approves image and data management/analysis platform ➤ Results from pivotal Phase 3 trial for new Demodex treatment ➤ Trial demonstrates safety, efficacy of mydriasis-reversal drug in pediatric patients ➤ Phase 3 pivotal trial for novel dry eye disease, MGD drug candidate ➤ Phase 3 results for investigational geographic atrophy therapy ➤ New coalition supports sustainability in…

➤ FDA approves new phaco system ➤ Next-generation canaloplasty device launch ➤ New Nd:YAG laser launch ➤ Researchers explore non-surgical option to address vision loss ➤ Non-invasive method to examine conjunctival goblet cells in vivo ➤ ASCRS news and events

➤ Phase 3 clinical trials complete for ‘superpotent’ corticosteroid ➤ New rapid, quantitative MMP-9 tear test ➤ First pediatric patient dosed with experimental gene-editing therapy for Leber congenital amaurosis ➤ Study: Comparison of NCX 470 to latanoprost for glaucoma ➤ Collaborations for inherited retinal diseases ➤ ASCRS news and events

➤ Topline data from Phase 3 trial of presbyopia-correcting drop ➤ FDA gives 510(K) approval to updated neuromodulation therapy for increased tear production ➤ Enrollment complete for Phase 3 trial of reproxalap ➤ DME trial to focus on underrepresented patient populations ➤ BLA submitted to FDA for wet AMD therapy ➤ Companies collaborate to further develop gene therapy for retinal disease ➤ ASCRS…

➤ FDA approves new ICL ➤ Home tonometer receives 510(k) clearance ➤ First patient treated in what will be the largest standalone MIGS clinical trial ➤ Topline results from second Phase 3 trial of mydriasis-reversing drug ➤ ASCRS news and events

➤ Launch of IOL made with new ‘glistening-free’ material ➤ Enrollment complete in study of mydriasis-reversing drop in a pediatric group ➤ Acquisition of electrophysiology medical device company ➤ Licensing of investigational neuroprotective drug ➤ ASCRS news and events

➤ FDA approves first drug-eluting contact lens ➤ FDA accepts 510(k) submission for new femto-phaco device ➤ Phase 2 study begins to evaluate an immunomodulatory agent for dry eye ➤ Licensing agreement for optic nerve-protective therapy ➤ Phase 3 study to evaluate protein replacement solution for dry eye ➤ Study: Impact of age on SMILE outcomes ➤ ASCRS news and events

➤ FDA accepts NDA for anesthesia, pain management drug ➤ Five-year results with intracanalicular microstent ➤ Request for information about ocular imaging ➤ Post-hoc analysis of NMOSD treatment ➤ Investigational visual prosthesis implanted in blind patient ➤ ASCRS news and events

➤ Nerve growth factor being studied as a possible treatment for Sjogren’s-related dry eye ➤ Investigational RNA therapy doesn’t meet primary endpoint ➤ Phase 1 clinical trial for bioerodible, sustained anti-VEGF delivery ➤ Positive interim data for diabetic retinopathy treatment ➤ Positive results in trial for high-dose aflibercept ➤ Additional Phase 3 trial data for Beovu in DME ➤ ASCRS news and…